Skip to main content
Premium Trial:

Request an Annual Quote

Sirna to Manufacture Aptamers for Archemix

NEW YORK, July 28 (GenomeWeb News) - Sirna Therapeutics said this week that it has signed an exclusive, four-year deal to manufacture all of Archemix's aptamers used through phase IIa clinical development. Sirna has additionally granted a worldwide, non-exclusive, perpetual license to its aptamer manufacture and commercialization intellectual property to Archemix.

 

The arrangement, said Sirna, follows an October 2003 deal under which Sirna manufactured Archemix's anti-thrombin aptamer, ARC183, for development up through phase IIa testing.

 

"Sirna's mission is to develop nucleic acid therapeutics based on RNA interference," Sirna senior vice president and COO Nassim Usman said in a statement. "Through our partnership and licensing agreement with Archemix ... Sirna will generate revenues as Archemix develops and commercializes its aptamer products."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.